Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Lobular breast carcinoma and its variants.

Rakha EA, Ellis IO.

Semin Diagn Pathol. 2010 Feb;27(1):49-61. Review.

PMID:
20306830
2.

The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type.

Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, Kreike B, Reis-Filho JS.

J Pathol. 2010 Jan;220(1):45-57. doi: 10.1002/path.2629.

PMID:
19877120
3.

Molecular mechanisms controlling E-cadherin expression in breast cancer.

Baranwal S, Alahari SK.

Biochem Biophys Res Commun. 2009 Jun 19;384(1):6-11. doi: 10.1016/j.bbrc.2009.04.051. Epub 2009 Apr 18. Review.

4.

Pleomorphic lobular carcinoma of the breast: molecular pathology and clinical impact.

Vargas AC, Lakhani SR, Simpson PT.

Future Oncol. 2009 Mar;5(2):233-43. doi: 10.2217/14796694.5.2.233. Review.

PMID:
19284381
5.

Refinement of breast cancer classification by molecular characterization of histological special types.

Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL.

J Pathol. 2008 Oct;216(2):141-50. doi: 10.1002/path.2407.

PMID:
18720457
6.

Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution.

Orvieto E, Maiorano E, Bottiglieri L, Maisonneuve P, Rotmensz N, Galimberti V, Luini A, Brenelli F, Gatti G, Viale G.

Cancer. 2008 Oct 1;113(7):1511-20. doi: 10.1002/cncr.23811.

7.

Is pleomorphic lobular carcinoma really a distinct clinical entity?

Buchanan CL, Flynn LW, Murray MP, Darvishian F, Cranor ML, Fey JV, King TA, Tan LK, Sclafani LM.

J Surg Oncol. 2008 Oct 1;98(5):314-7. doi: 10.1002/jso.21121.

PMID:
18668643
8.

Lack of prognostic significance of "classic" lobular breast carcinoma: a matched, single institution series.

Viale G, Rotmensz N, Maisonneuve P, Orvieto E, Maiorano E, Galimberti V, Luini A, Colleoni M, Goldhirsch A, Coates AS.

Breast Cancer Res Treat. 2009 Sep;117(1):211-4. doi: 10.1007/s10549-008-0112-4. Epub 2008 Jul 16.

PMID:
18629634
9.

Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles.

Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC, Bibeau F, Mathieu MC, Treilleux I, Jacquemier J, Ursule L, Martinec A, Wang Q, Bénard J, Puisieux A, Birnbaum D, Theillet C.

Oncogene. 2008 Sep 11;27(40):5359-72. doi: 10.1038/onc.2008.158. Epub 2008 May 19.

10.

Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas.

Simpson PT, Reis-Filho JS, Lambros MB, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Dexter T, Jones A, Reid L, Da Silva L, Shin SJ, Hardisson D, Ashworth A, Schmitt FC, Palacios J, Lakhani SR.

J Pathol. 2008 Jul;215(3):231-44. doi: 10.1002/path.2358.

PMID:
18473330
11.

Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thürlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group.

J Clin Oncol. 2008 Jun 20;26(18):3006-14. doi: 10.1200/JCO.2007.14.9336. Epub 2008 May 5.

PMID:
18458044
12.

Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?

Tang P, Wang J, Bourne P.

Hum Pathol. 2008 Apr;39(4):506-13. doi: 10.1016/j.humpath.2007.09.005. Epub 2008 Mar 4.

PMID:
18289638
13.

The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?

Fadare O, Wang SA, Hileeto D.

Hum Pathol. 2008 Mar;39(3):331-6. doi: 10.1016/j.humpath.2007.07.014.

PMID:
18261623
14.

Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.

Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO.

Eur J Cancer. 2008 Jan;44(1):73-83. Epub 2007 Nov 26.

PMID:
18035533
15.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34.

17.

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.

Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM.

Clin Cancer Res. 2007 Apr 15;13(8):2329-34.

19.

Triple-negative breast cancer: therapeutic options.

Cleator S, Heller W, Coombes RC.

Lancet Oncol. 2007 Mar;8(3):235-44. Review.

PMID:
17329194
20.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF; American Society of Clinical Oncology; College of American Pathologists.

J Clin Oncol. 2007 Jan 1;25(1):118-45. Epub 2006 Dec 11.

PMID:
17159189

Supplemental Content

Support Center